Achieve Life Sciences ACHV Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Achieve Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Achieve Life Sciences’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Achieve Life Sciences's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Achieve Life Sciences's additional paid-in capital?
- Achieve Life Sciences (ACHV) reported additional paid-in capital of $280.95M in Q1 2026.
- How has Achieve Life Sciences's additional paid-in capital changed year-over-year?
- Achieve Life Sciences's additional paid-in capital increased by 22.9% year-over-year, from $228.58M to $280.95M.
- What is the long-term trend for Achieve Life Sciences's additional paid-in capital?
- Over 5 years (2020 to 2025), Achieve Life Sciences's additional paid-in capital has grown at a 23.6% compound annual growth rate (CAGR), from $97.64M to $281.61M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.